Aprielle B Wills1,2, Alicen B Spaulding1,2, Jennifer Adjemian1,2,3, D Rebecca Prevots1,2, Siu-Ping Turk2, Carla Williams4, Adriana Marques2. 1. Epidemiology Unit. 2. Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda. 3. US Public Health Service, Commissioned Corps, Rockville. 4. Clinical Monitoring Research Program, Leidos Biomedical Research Inc., National Cancer Institute, Frederick, Maryland.
Abstract
BACKGROUND: Lyme disease is the most common vector-borne disease in the United States. Some patients report persistent or intermittent subjective symptoms of mild to moderate intensity after antibiotic treatment for Lyme disease. We sought to evaluate trends in clinical and quality-of-life (QOL) measures in a cohort of patients with Lyme disease enrolled in a natural history study at the National Institutes of Health from 2001-2014. METHODS: QOL was measured using the self-administered 36-item Short Form Health Survey (SF-36) during study follow-up. Primary outcomes included mean physical (PCS) and mental (MCS) health QOL composite scores and reporting long-term (≥2 years) symptoms, adjusted for Lyme disease stage and severity at diagnosis. RESULTS: Overall, 101 patients with an average follow-up time of 3.9 years (range, 0.5-11.3 years) were included. At first visit, overall mean QOL scores were below the US population mean for both PCS (45.6 ± 10.4) and MCS (47.3 ± 11.5) but increased to just above the national average after 3 years of follow-up for both PCS (50.7 ± 9.6) and MCS (50.1 ± 10.0). Baseline QOL scores were lowest in those with late disease (P < 0.01) but also increased by the end of follow-up to national averages. In multivariate analysis, the only factors significantly associated with long-term symptoms or lower QOL scores were other comorbidities unrelated to Lyme disease. CONCLUSIONS: Comorbid conditions can play a role in the reporting of long-term symptoms and overall QOL of Lyme disease patients and should be considered in the evaluation of these patients. CLINICAL TRIALS REGISTRATION: NCT00028080. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND:Lyme disease is the most common vector-borne disease in the United States. Some patients report persistent or intermittent subjective symptoms of mild to moderate intensity after antibiotic treatment for Lyme disease. We sought to evaluate trends in clinical and quality-of-life (QOL) measures in a cohort of patients with Lyme disease enrolled in a natural history study at the National Institutes of Health from 2001-2014. METHODS: QOL was measured using the self-administered 36-item Short Form Health Survey (SF-36) during study follow-up. Primary outcomes included mean physical (PCS) and mental (MCS) health QOL composite scores and reporting long-term (≥2 years) symptoms, adjusted for Lyme disease stage and severity at diagnosis. RESULTS: Overall, 101 patients with an average follow-up time of 3.9 years (range, 0.5-11.3 years) were included. At first visit, overall mean QOL scores were below the US population mean for both PCS (45.6 ± 10.4) and MCS (47.3 ± 11.5) but increased to just above the national average after 3 years of follow-up for both PCS (50.7 ± 9.6) and MCS (50.1 ± 10.0). Baseline QOL scores were lowest in those with late disease (P < 0.01) but also increased by the end of follow-up to national averages. In multivariate analysis, the only factors significantly associated with long-term symptoms or lower QOL scores were other comorbidities unrelated to Lyme disease. CONCLUSIONS: Comorbid conditions can play a role in the reporting of long-term symptoms and overall QOL of Lyme diseasepatients and should be considered in the evaluation of these patients. CLINICAL TRIALS REGISTRATION: NCT00028080. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Entities:
Keywords:
Borrelia burgdorferi; Lyme disease; epidemiology; longitudinal analysis; quality of life
Authors: Gary P Wormser; Raymond J Dattwyler; Eugene D Shapiro; John J Halperin; Allen C Steere; Mark S Klempner; Peter J Krause; Johan S Bakken; Franc Strle; Gerold Stanek; Linda Bockenstedt; Durland Fish; J Stephen Dumler; Robert B Nadelman Journal: Clin Infect Dis Date: 2006-10-02 Impact factor: 9.079
Authors: Gary P Wormser; Roshan Ramanathan; John Nowakowski; Donna McKenna; Diane Holmgren; Paul Visintainer; Rhea Dornbush; Brij Singh; Robert B Nadelman Journal: Ann Intern Med Date: 2003-05-06 Impact factor: 25.391
Authors: J Oksi; J Nikoskelainen; H Hiekkanen; A Lauhio; M Peltomaa; A Pitkäranta; D Nyman; H Granlund; S-A Carlsson; I Seppälä; V Valtonen; M Viljanen Journal: Eur J Clin Microbiol Infect Dis Date: 2007-08 Impact factor: 3.267
Authors: Michael C Sneller; Cavan Reilly; Moses Badio; Rachel J Bishop; Allen O Eghrari; Soka J Moses; Kumblytee L Johnson; Dehkontee Gayedyu-Dennis; Lisa E Hensley; Elizabeth S Higgs; Avindra Nath; Kaylie Tuznik; Justin Varughese; Kenneth S Jensen; Bonnie Dighero-Kemp; James D Neaton; H Clifford Lane; Mosoka P Fallah Journal: N Engl J Med Date: 2019-03-07 Impact factor: 91.245
Authors: Sarah K Whiteside; Jeremy P Snook; Ying Ma; F Lynn Sonderegger; Colleen Fisher; Charisse Petersen; James F Zachary; June L Round; Matthew A Williams; Janis J Weis Journal: J Immunol Date: 2018-01-12 Impact factor: 5.422
Authors: Alison W Rebman; Kathleen T Bechtold; Ting Yang; Erica A Mihm; Mark J Soloski; Cheryl B Novak; John N Aucott Journal: Front Med (Lausanne) Date: 2017-12-14